An Image To Maintain: GAO Profit Picture Of Drug Industry Is Good To Store Away For Future Debates
Executive Summary
Big pharma has been highly successful at changing the debate from the level of drug company profitability to who shares what part of dollars generated by drug sales, but there are still lingering efforts to define and describe overall drug industry profitability and put it in the overall context of the broader economy. These efforts are backburner for now but will come back at some point in the future. Some of the portrayals are friendlier to pharma than others.
You may also be interested in...
Pricing Debate: GAO Report On Rx Profits Offers Ammunition To Both Sides
Sen. Sanders and Rep. Cummings requested the study, which notes industry's healthy margins and offers concerns about mergers – but emphasizes the increasing cost of R&D.
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.
As Sickle Cell Gene Therapies Move To Market, Health Inequities Could Help Pricing Debate
Positive tandem ICER reviews for bluebird bio’s and Vertex/CRISPR’s gene therapies show the impact that concerns about addressing racial inequities could create a favorable context for products as they enter pricing and coverage discussions.